Cipla shares rose after USFDA approved its first AB rated generic Ventolin HFA inhaler, to launch in US by first half FY27, targeting a $1.5 billion market.
Cipla shares rose after USFDA approved its first AB rated generic Ventolin HFA inhaler, to launch in US by first half FY27, targeting a $1.5 billion market.